Avibactam Tomilopil(Avibactam Tomilopil) - 药物靶点：β-lactamase_在研适应症：复杂的尿路感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CTB+AVP、PF-06264006+PF-07338233

+ [1]

靶点

β-lactamase

作用机制

β-lactamase抑制剂(β-内酰胺酶抑制剂)

治疗领域

感染泌尿生殖系统疾病

在研适应症

复杂的尿路感染

非在研适应症-

原研机构

Pfizer Inc.

在研机构

Pfizer Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H23N3O8S

InChIKeyJHSLCXRZVJOZQZ-ZJUUUORDSA-N

CAS号2245880-46-8

关联

3

项与 Avibactam Tomilopil 相关的临床试验

NCT06593054 / Active, not recruiting临床1期

An Interventional Open-Label, Single-Dose, 4-Treatment, 4-Period Crossover Study to Evaluate the Relative Bioavailability of CTB and AVI Administered Via Various Tablets or Capsule Formulations of PF-07612577 (PF-06264006 [CTB] - PF-07338233 [AVP]) and the Effect of Food on the Bioavailability of CTB and AVI Administered Via Tablets in Healthy Adult Participants

The purpose of this study is to learn about the study medicine CTB-AVP for the treatment of severe urinary tract infections that require hospitalization.
This study is seeking for:
* adult male and female participants who are healthy and weigh more than 50 kg.
* participants who have normal blood pressure, normal kidney and liver function
* participants willing to stay away from caffeine and other medicines for the duration of the study.
Participants will be required to stay in the study clinic for two weeks. All participants in this study will receive study medicine CTB-AVP by mouth one time each day on four different days. Study medicine will be given in capsules or tablets, on an empty stomach or will be taken with a meal. The study will look at the experiences of people receiving the study medicine. This will help determine if the study medicine is safe and effective.

开始日期2024-07-29

申办/合作机构

Pfizer Inc.

NCT05554237 / Completed临床1期

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07612577 (PF-06264006 [CTB] + PF-07338233 [AVP]) IN HEALTHY ADULT PARTICIPANTS

The purpose of this clinical trial is to learn about the pharmacokinetics, safety and tolerability of various single- and multiple-doses of CTB+AVP in healthy adult participants. CTB+AVP is a study medicine that is being developed to treat people with complicated urinary tract infections.
This study is seeking healthy adult male and female participants, 18-60 years of age, with a body weight > 50 kg and a BMI of 17.5 to 30.5 kg/m2.
Participants in Part-1 of the study will receive increasing single doses of CTB and/or AVP. Participants in Part-2 will receive increasing multiple doses of CTB+AVP three times a day for 7 days. The study team will monitor how each participant is doing with the study treatments via close monitoring in an in-patient setting. Experiences of people receiving CTB+AVP will be compared to those of people who do not. This will help determine if CTB+AVP is safe and well-tolerated at each dose of the study medicine.
Participants will take part in this study for a maximum of 12 weeks for Part-1 (up to 4 weeks for screening, up to 3 weeks of taking study medicine and up to 5 weeks for safety follow-up visit) and for a maximum of 10 weeks for Part-2 (up to 4 weeks for screening, up to 1 week of taking study medicine and up to 5 weeks for safety follow-up visit). During the duration of the study, blood samples for study medicine levels, and various measures for monitoring safety such as blood samples for clinical laboratory measurements, electrocardiograms and vital sign measurements will be taken.

开始日期2022-10-07

申办/合作机构

Pfizer Inc.

ISRCTN10278402 / Completed临床4期IIT

Assessment of the effect of prior anthrax vaccine precipitated (AVP) vaccination on the immune response to booster AVP vaccination: an open-label trial

开始日期2009-05-02

申办/合作机构-

100 项与 Avibactam Tomilopil 相关的临床结果

登录后查看更多信息

100 项与 Avibactam Tomilopil 相关的转化医学

登录后查看更多信息

100 项与 Avibactam Tomilopil 相关的专利（医药）

登录后查看更多信息

3,345

项与 Avibactam Tomilopil 相关的文献（医药）

2024-08-01·Nature Reviews Endocrinology

Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency

Review

作者: Atila, Cihan ; Refardt, Julie ; Christ-Crain, Mirjam

Polyuria-polydipsia syndrome can be caused by central diabetes insipidus, nephrogenic diabetes insipidus or primary polydipsia. To avoid confusion with diabetes mellitus, the name 'central diabetes insipidus' was changed in 2022 to arginine vasopressin (AVP) deficiency and 'nephrogenic diabetes insipidus' was renamed as AVP resistance. To differentiate the three entities, various osmotic and non-osmotic copeptin-based stimulation tests have been introduced in the past decade. The hypertonic saline test plus plasma copeptin measurement emerged as the test with highest diagnostic accuracy, replacing the water deprivation test as the gold standard in differential diagnosis of the polyuria-polydipsia syndrome. The mainstay of treatment for AVP deficiency is AVP replacement with desmopressin, a synthetic analogue of AVP specific for AVP receptor 2 (AVPR2), which usually leads to rapid improvements in polyuria and polydipsia. The main adverse effect of desmopressin is dilutional hyponatraemia, which can be reduced by regularly performing the so-called desmopressin escape method. Evidence from the past few years suggests an additional oxytocin deficiency in patients with AVP deficiency. This potential deficiency should be further evaluated in future studies, including feasible provocation tests for clinical practice and interventional trials with oxytocin substitution.

2024-07-01·Journal of Diabetes Science and Technology

An Augmented Vision of Our Medical and Surgical Future, Today?

Article

作者: Casini, Andrea ; Armstrong, David G ; Clerici, Giacomo ; Pillai, Anand ; Bazikian, Sebouh ; Armstrong, Alexandria A

Incorporating consumer electronics into the operating room, we evaluated the Apple Vision Pro (AVP) during limb preservation surgeries, just as we evaluated Google Glass and FaceTime more than a decade ago. Although AVP’s real-time mixed-reality data overlay and controls offer potential enhancements to surgical precision and team communication, our assessment recognized limitations in adapting consumer technology to clinical environments. The initial use facilitated intraoperative decision-making and educational interactions with trainees. The current mixed-reality pass-through resolution allows for input but not for highly dexterous surgical interactions. These early observations indicate that while AVP may soon improve aspects of surgical performance and education, further iteration, evaluation, and experience are needed to fully understand its impact on patient outcomes and to refine its integration into clinical practice.

2024-07-01·International Journal of Cardiology

The axillary vein puncture for implantable cardiac defibrillator implantation: 14 years of experience. Analysis of the results

Article

作者: Morani, Giovanni ; Pepe, Antonio ; Bolzan, Bruna ; Strazzanti, Mattia ; Berton, Giampaolo ; Ribichini, Flavio Luciano

BACKGROUNDAxillary vein puncture (AVP) is a valid alternative to Subclavan vein puncture for leads insertion in cardiac implantable electronic device implantation, that may reduce acute and delayed complications. Very few data are available about ICD recipients. A simplified AVP technique is described.METHODSAll the patients who consecutively underwent "de novo" ICD implantation, from March 2006 to December 2020 at the University of Verona, were considered. Leads insertion was routinely performed through an AVP, according to a simplified technique. Outcome and complications have been retrospectively analyzed.RESULTSThe study population consisted of 1711 consecutive patients. Out of 1711 patients, 38 (2.2%) were excluded because they were implanted with Medtronic Sprint Fidelis lead. Out of 1673 ICD implantations, 963 (57.6%) were ICD plus cardiac resynchronization therapy, 434 (25.9%) were dual-chamber defibrillators, and 276 (16.5%) were single-chamber defibrillators, for a total of 3879 implanted leads. The AVP success rate was 99.4%. Acute complications occurred in 7/1673 (0.42%) patients. Lead failure (LF) occurred in 20/1673 (1.19%) patients. Comparing the group of patients with lead failure with the group without LF, the presence of three leads inside the vein was significantly associated with LF, and the multivariate analysis confirmed three leads in place as an independent predictor of LF.CONCLUSIONAVP, according to our simplified technique, is safe, effective, has a high success rate, and a very low complication rate. The incidence of LF was exceptionally low. The advantages of AVP are maintained over time in a population of ICD recipients.

100 项与 Avibactam Tomilopil 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复杂的尿路感染	临床1期	比利时	Pfizer Inc.	2022-09-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2020	N/A	-	43	AVP use post DDKT	網壓獵積艱顧簾襯淵築(鹽顧鬱淵鹽艱鹹襯範廠) = 鬱獵觸壓選壓憲窪糧製鹹鏇製網齋糧積鑰膚夢 (糧衊鹽憲艱憲餘網積願 ) 更多	积极	2020-10-19
ARVO2015	N/A	-	-	PBS	廠糧餘鹹積簾鏇膚蓋憲(糧齋醖遞築窪艱簾廠膚) = 繭製憲構蓋餘蓋糧餘窪餘鏇壓獵觸鏇鏇醖獵醖 (築鹽淵鏇壓夢繭築襯鏇 )	-	2015-06-01
				AVP	廠糧餘鹹積簾鏇膚蓋憲(糧齋醖遞築窪艱簾廠膚) = 願醖糧襯壓網齋鹽鏇鹹餘鏇壓獵觸鏇鏇醖獵醖 (築鹽淵鏇壓夢繭築襯鏇 )
AAN2014	临床3期	急性偏头痛	223	AVP-825 22 mg	鹹衊遞襯構廠夢觸艱襯(鬱獵繭醖網製選餘壓衊) = 醖構齋簾網網鑰築淵壓醖夢網餘淵顧範淵製鑰 (簾醖遞鹹糧餘鏇範齋夢 ) 更多	积极	2014-04-08
				Placebo	鹹衊遞襯構廠夢觸艱襯(鬱獵繭醖網製選餘壓衊) = 繭廠廠網齋齋壓糧構膚醖夢網餘淵顧範淵製鑰 (簾醖遞鹹糧餘鏇範齋夢 ) 更多